Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ilias Evmorfiadis"'
Autor:
Klearchos Psychogios, Athanasios Stavridis, Spyros Dragomanovits, Konstantinos Takis, Pantelis Stathis, Loukas Kaklamanis, Ilias Evmorfiadis
Publikováno v:
Journal of Stroke and Cerebrovascular Diseases. 26:e47-e49
Eosinophilic granulomatosis with polyangiitis (EGPA, previously named Churg-Strauss syndrome) is a form of necrotizing vasculitis occurring in patients with asthma and eosinophilia. Ischemic stroke is a relatively rare complication of the disease. We
Autor:
Ilias Evmorfiadis, Elias Kotteas, Andriani Charpidou, Paraskevi Boura, Patrick Van Dreden, Grigoris T. Gerotziafas, Dimitra Grapsa, Annette K. Larsen, Anna Falanga, Ismail Elalamy, Theodoros N. Sergentanis, Konstantinos N. Syrigos, Rabiatou Sangare
Publikováno v:
Oncologist
Oncologist, AlphaMed Press, 2018, 23 (11), pp.1372-1381. ⟨10.1634/theoncologist.2017-0530⟩
Oncologist, AlphaMed Press, 2018, 23 (11), pp.1372-1381. ⟨10.1634/theoncologist.2017-0530⟩
Background The aim of this prospective study was to identify the most clinically relevant hypercoagulability biomarkers in lung adenocarcinoma patients for elaboration of an improved risk assessment model (RAM) for venous thromboembolism (VTE). Subje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b119afcb4a690679c95b622a0a85762c
https://hal.sorbonne-universite.fr/hal-01989912/document
https://hal.sorbonne-universite.fr/hal-01989912/document
Autor:
Paraskevi Boura, Patrick Van Dreden, Rabiatou Sangare, Annette K. Larsen, Grigoris T. Gerotziafas, Aurélie Rousseau, Konstantinos N. Syrigos, Ioannis Gkiozos, Andriani Charpidou, Ismail Elalamy, Ilias Evmorfiadis
Publikováno v:
Journal of Clinical Oncology. 34:e23271-e23271
e23271Background: In ambulatory patients with advanced or metastatic stage of lung adenocarcinoma (LA) the risk of VTE increases during chemotherapy. but individual risk factors cannot identify pat...
Autor:
Ismail Elalany, Paraskey Boura, Rabiatou Sangare, Ioannis Gkiozos, Ilias Evmorfiadis, Patrick Van Dreden, Konstantinos N. Syrigos, Grigoris T. Gerotziafas, Aurélie Rousseau, Andriani Charpidou, Annette K. Larsen
Publikováno v:
Journal of Clinical Oncology. 34:e23073-e23073
e23073Background: In ambulatory patients with lung adenocarcinoma (LA) the risk of VTE increases during chemotherapy (CTx). The identification of clinically relevant biomarkers of hypercoagulabilit...
Autor:
Flora Zagouri, Patrick Van Dreden, Aurélie Rousseau, Kimon Stamatelopoulos, Ismail Elalamy, Grigorios T. Gerotziafas, Efstathios Kastritis, Despina Fotiou, Evangelos Terpos, Meletios A. Dimopoulos, Theodora Psaltopoulou, Ilias Evmorfiadis, Annette K. Larsen, Theodoros N. Sergentanis
Publikováno v:
Blood. 126:1074-1074
Background: Multiple myeloma (MM) and plasma cell dyscrasias (PCD) are associated with increased risk of venous thromboembolism (VTE) which is further enhanced by treatments with immunomodulatory agents, melphalan or steroids. The optimization of VTE
Autor:
Kalliopi N. Manola, Vasileios N. Georgakakos, Katerina Zoi, Chryssa Stavropoulou, Gabriel E. Pantelias, Ilias Evmorfiadis, Constantina Sambani, Katy Stefanoudaki, Christine Zoi, Markos Fisfis
Publikováno v:
Leukemia research. 31(7)
We report a JAK2 V617F-negative case of polycythemia vera with two acquired balanced X-autosome translocations and no history of previous exposure to chemo/radiotherapy. The patient's first clone carried a novel translocation t(X;15)(q24;q13) as a so
Autor:
Patrick Van Dreden, Ilias Evmorfiadis, Giannis Giozos, Ariadni Charpidou, Konstantinos N. Syrigos, Matthieu Grusse, Grigorios T. Gerotziafas, Paraskevi Boura, Ismail Elalamy, Aurélie Rousseau, Anastasia Spanoudaki
Publikováno v:
Blood. 124:4253-4253
Introduction. In patients with lung adenocarcinoma, metastasis, advanced stage and chemotherapy (CTx) are factors which increase the risk of venous thromboembolism (VTE). However, routine pharmacological thromboprophylaxis is not recommended but indi
Autor:
Dimitra Karipidi, Vassiliki Galea, Ismail Elalamy, Patrick Van Dreden, Ilias Evmorfiadis, Grigoris T. Gerotziafas, Severin Bouffard, Amir Kartechi, Marie-Paule Roman
Publikováno v:
Blood. 122:3631-3631
Background Clopidogrel is cornerstone treatment for atherothrombotic patients. The incidence of recurrent thrombotic events raises up to 10% of patients on treatment with clopidogrel. Intestinal absorption via the glycoproteine ABCB1, bioactivation b